View Older Stories View More Recent Stories

Nov 20, 2019 06:45AM European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Nov 19, 2019 12:43PM Merck Announces First-Quarter 2020 Dividend
Nov 18, 2019 06:31AM Merck (MRK), Bayer’s Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 18, 2019 06:30AM Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 15, 2019 06:46AM Merck's (MRK) BRAVECTO PLUS for Cats Receives Approval from US FDA
Nov 15, 2019 06:45AM BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration
Nov 14, 2019 06:55AM US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review
Nov 12, 2019 08:00AM MilliporeSigma Licenses CRISPR Gene-Editing Technology to Evotec
Nov 11, 2019 03:02PM Merck's (MRK) ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in European Union
Nov 11, 2019 03:00PM Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Nov 8, 2019 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 29, 2019 06:45AM Merck Announces Third-Quarter 2019 Financial Results
Oct 28, 2019 02:00PM European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 18, 2019 07:02AM Merck (MRK) Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA as First-Line Treatment for Metastatic or Unresectable Recurrent HNSCC
Oct 18, 2019 07:00AM Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Oct 18, 2019 06:45AM Merck (MRK) Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine
Oct 18, 2019 06:45AM Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
Oct 10, 2019 07:30AM NexTech Appoints New Chief Financial Officer
Oct 8, 2019 08:00AM Merck Issues 2018/2019 Corporate Responsibility Report
Oct 2, 2019 10:44AM Agilent Technologies (A) Granted Approval for First PD-L1 Companion Diagnostic in China
Oct 2, 2019 06:48AM Merck's (MRK) KEYTRUDA Now Approved in China for First-Line Treatment of Certain Patients with Advanced NSCLC Whose Tumors Express PD-L1
Oct 2, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Oct 2, 2019 06:31AM Merck (MRK) Announces FDA Accepts Two Applications for its DIFICID to Treat Children with Clostridium difficile Infections
Oct 2, 2019 06:30AM FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections
Oct 1, 2019 06:55AM Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29
Sep 30, 2019 10:32AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA More Than Doubled Median rPFS in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care
Sep 30, 2019 10:30AM LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)
Sep 30, 2019 06:55AM Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 30, 2019 06:49AM Merck (MRK) Announces Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO in HABP/VABP Met Primary Endpoint
Sep 30, 2019 06:45AM Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint
Sep 30, 2019 06:37AM Merck's (MRK) KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage TNBC
Sep 29, 2019 10:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Nega
Sep 29, 2019 02:30AM Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Sep 28, 2019 10:30AM LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer
Sep 27, 2019 02:00AM New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 20, 2019 08:11AM Merck KGaA, Pfizer (PFE) Announce CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients with Advanced RCC
Sep 20, 2019 08:10AM CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Sep 20, 2019 06:46AM Merck's (MRK) PIFELTRO and DELSTRIGO Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Sep 20, 2019 06:45AM Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically
Sep 18, 2019 06:21AM Merck (MRK) Announces FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 17, 2019 05:56PM FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 17, 2019 06:46AM Merck (MRK) Announces FDA Accepts its BLA and Grants Priority Review for V920 Vaccine for Ebola Zaire Virus
Sep 17, 2019 06:45AM FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Sep 10, 2019 08:00AM Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US
Sep 10, 2019 06:48AM Merck (MRK) Pooled Analysis Continues to Show its KEYTRUDA in Combination with Chemotherapy Improved OS for Patients with Advanced NSCLC
Sep 10, 2019 06:45AM Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Ad
Sep 9, 2019 06:48AM Merck (MRK) Announces Pivotal New Data from its Broad Oncology Portfolio at ESMO
Sep 9, 2019 06:45AM Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Sep 5, 2019 06:45AM Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Sep 4, 2019 06:51AM Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC
View More Recent Stories View Older Stories